XOMA Corp (OQ:XOMA)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: Suite 310, 2200 Powell Street
EMERYVILLE CA 94608
Tel: N/A
Website: https://www.xoma.com
IR: See website
<
Key People
Owen P. Hughes
Chief Executive Officer, Director
Thomas Burns
Chief Financial Officer, Senior Vice President - Finance
Bradley J. Sitko
Chief Investment Officer
Business Overview
XOMA Corporation is a biotechnology royalty aggregator. The Company's royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).
Financial Overview
For the fiscal year ended 31 December 2023, XOMA Corp revenues decreased 21% to $4.8M. Net loss applicable to common stockholders increased from $22.6M to $46.3M. Revenues reflect United States segment decrease of 18% to $3.7M, Asia Pacific segment decrease of 29% to $1.1M. Higher net loss reflects Stock-based Compensation in SGA increase from $3.6M to $9.1M (expense), Amortization of Intangible Assets increase from $97K to $897K (expense).
Employees: 13 as of Mar 4, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $242.01M as of Dec 31, 2023
Annual revenue (TTM): $4.76M as of Dec 31, 2023
EBITDA (TTM): -$25.12M as of Dec 31, 2023
Net annual income (TTM): -$46.30M as of Dec 31, 2023
Free cash flow (TTM): -$23.63M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 11,625,826 as of Mar 4, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.